124 related articles for article (PubMed ID: 31299412)
1. Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.
Shiseki M; Ishii M; Okada M; Ohwashi M; Wang YH; Osanai S; Yoshinaga K; Mori N; Motoji T; Tanaka J
Leuk Res; 2019 Sep; 84():106175. PubMed ID: 31299412
[TBL] [Abstract][Full Text] [Related]
2. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
[TBL] [Abstract][Full Text] [Related]
3. Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.
Shiseki M; Ishii M; Miyazaki M; Osanai S; Wang YH; Yoshinaga K; Mori N; Tanaka J
Cancer Med; 2020 Jan; 9(2):460-468. PubMed ID: 31755660
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
6. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
7. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
[TBL] [Abstract][Full Text] [Related]
8. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes.
Nacheva E; Holloway T; Carter N; Grace C; White N; Green AR
Cancer Genet Cytogenet; 1995 Apr; 80(2):87-94. PubMed ID: 7736443
[TBL] [Abstract][Full Text] [Related]
11. The GNAS1 gene in myelodysplastic syndromes (MDS).
Di Giacomo D; Lema Fernandez AG; Pierini T; Crescenzi B; Brandimarte L; Matteucci C; Testoni N; Mecucci C
Leuk Res; 2014 Jul; 38(7):804-7. PubMed ID: 24795070
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome of del 20q with plasma cell dysplasia.
Saito N; Higashiura K; Ehata K; Kurosawa S; Honma K; Abe M; Kimura A; Suzuki M; Nakamura S; Shiku H; Kean Ooi H
J Clin Exp Hematop; 2011; 51(2):141-5. PubMed ID: 22104314
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I; Villamón E; Abellán R; Calasanz MJ; Irigoyen A; Sanz G; Such E; Mora E; Gutiérrez M; Collado R; García-Serra R; Vara M; Blanco ML; Oiartzabal I; Álvarez S; Bernal T; Granada I; Xicoy B; Jerez A; Calabuig M; Diez R; Gil Á; Díez-Campelo M; Solano C; Tormo M;
Br J Haematol; 2021 Aug; 194(4):708-717. PubMed ID: 34296432
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG).
Bench AJ; Nacheva EP; Hood TL; Holden JL; French L; Swanton S; Champion KM; Li J; Whittaker P; Stavrides G; Hunt AR; Huntly BJ; Campbell LJ; Bentley DR; Deloukas P; Green AR
Oncogene; 2000 Aug; 19(34):3902-13. PubMed ID: 10952764
[TBL] [Abstract][Full Text] [Related]
15. A comparison of two contrasting recurrent isochromosomes 20 found in myelodysplastic syndromes suggests that retention of proximal 20q is a significant factor in myeloid malignancies.
MacKinnon RN; Campbell LJ
Cancer Genet Cytogenet; 2005 Dec; 163(2):176-9. PubMed ID: 16337864
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and cytogenetic features of 29 cases of myelodysplastic syndrome associated with del(20q)].
Qin S; Liu SH; Bo LJ; Liu XP; Li CW; Dai Y; He GS; Shao ZH
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Apr; 21(2):171-2. PubMed ID: 15079804
[TBL] [Abstract][Full Text] [Related]
17. Dicentric chromosomes and 20q11.2 amplification in MDS/AML with apparent monosomy 20.
Mackinnon RN; Campbell LJ
Cytogenet Genome Res; 2007; 119(3-4):211-20. PubMed ID: 18253031
[TBL] [Abstract][Full Text] [Related]
18. Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes.
Saunders K; Czepulkowski B; Sivalingam R; Hayes JP; Aldouri M; Sekhar M; Cummins M; Ho A; Mufti GJ
Cancer Genet Cytogenet; 2005 Jan; 156(2):154-7. PubMed ID: 15642396
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome.
Douet-Guilbert N; Laï JL; Basinko A; Gueganic N; Andrieux J; Pollet B; Plantier I; Delattre C; Crépin O; Corm S; Le Bris MJ; Morel F; De Braekeleer M
Br J Haematol; 2008 Dec; 143(5):716-20. PubMed ID: 19036015
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
Pitchford CW; Hettinga AC; Reichard KK
Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
